An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.
Prostate cancer (PC) remains a significant health concern as the second leading cause of cancer-related death in American men. Androgen deprivation therapies represent the standard of care for patients with PC, regardless of disease stage. Gonadotropin-releasing hormone (GnRH) antagonists, such as Degarelix, are commonly used hormone therapies for PC and work by suppressing testosterone…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.